REMS In The Slow Lane: Majority Of "Deemed" Products Still Not "Converted"
This article was originally published in The Pink Sheet Daily
Executive Summary
But FDA says it hopes that several will be switched within the next few months.
You may also be interested in...
Cephalon’s Fentanyl Drugs Join Class-Wide REMS; Shared System Still To Come
Cephalon’s Actiq and Fentora will undergo increased distribution restrictions after joining FDA’s class-wide REMS for transmucosal fentanyl drugs, but a shared system, one of the main tenets of the risk management plan, is still under development.
Cephalon’s Fentanyl Drugs Join Class-Wide REMS; Shared System Still To Come
Cephalon’s Actiq and Fentora will undergo increased distribution restrictions after joining FDA’s class-wide REMS for transmucosal fentanyl drugs, but a shared system, one of the main tenets of the risk management plan, is still under development.
Gilead's Letairis Gets Boost Against Actelion's Tracleer With Removal Of Liver Warning
REMS helps drive the endothelin receptor antagonist to a cleaner label, as the pulmonary arterial hypertension drug's black box will be modified and liver testing requirements dropped.